News

NexoBrid is indicated to remove eschar in paediatric and adult patients with deep-partial and full-thickness thermal burns without surgery. Japan is claimed to be the world’s first country

The treatment is intended for such patients who have previously received two or more lines of systemic therapy. The JNDA filing is backed by the multicentre, open-label Phase

Under the deal, Vistagen will offer nearly 12.4 million shares of the company’s common stock as well as a nominal cash payment. Pherin works on discovering and developing

Kite will purchase all outstanding shares of Tmunity other than those the company already owns. The acquisition complements the existing in-house cell therapy research capabilities of Kite with

ENHERTU is a particularly engineered HER2 directed antibody drug conjugate (ADC) being jointly developed and commercialised by the two firms. Around 136,000 cases of gastric cancer are diagnosed

Innovate UK awarded the grant as part of its Biomedical Catalyst 2022 research and development (R&D) competition. Alchemab is currently undertaking the preclinical studies to progress its antibodies

The company has also received additional funding from JLS Fund, Gron Ventures, Alumni Ventures, Palo Santo, Satori Capital, Negev Capital, and Route 66. It intends to use the

As per the strategic partnership and license agreement terms, Innovent will obtain an exclusive right for developing and commercialising the therapy in China. For the China rights, LG

Spesolimab has been developed to block the interleukin-36 receptor (IL-36R) activation. IL-36R is a signalling pathway in the immune system that is involved in the pathogenesis of many